Progressive supranuclear palsy (PSP) is an uncommon brain disorder. It affects many areas of function, including a person's ...

FNP-223 is currently being investigated in a phase 2 trial evaluating the treatment in adults with possible or probable PSP-Richardson syndrome.

Kinetic measures of a cerebrospinal fluid (CSF) biomarker test predicted cognitive decline in Parkinson's disease and ...

Distinct patterns of brain inflammation identified through PET imaging may explain disease progression and severity in ...

Sunday, May 18, 2025. News & Perspective Drugs & Diseases CME & Education Drugs & Diseases CME & Education ...

The Key Progressive Supranuclear Palsy Companies in the market include - Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma ...

Find all the latest on progressive supranuclear palsy at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.

A novel PET imaging study has identified unique patterns of neuroinflammation in patients with progressive apraxia of speech ...

PSP progressive supranuclear palsy, PD Parkinson's disease, HOA healthy older adult, DS double support percentage of gait cycle, n/s not statistically significant. Tables. Table 2.